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OBJECTIVE—TBC1D1 is a member of the TBC1 Rab-GTPase
family of proteins and is highly expressed in skeletal muscle.
Insulin and contraction increase TBC1D1 phosphorylation on
phospho-Akt substrate motifs (PASs), but the function of
TBC1D1 in muscle is not known. Genetic linkage analyses show
a TBC1D1 R125W missense variant confers risk for severe
obesity in humans. The objective of this study was to determine
whether TBC1D1 regulates glucose transport in skeletal muscle.
RESEARCH DESIGN AND METHODS—In vivo gene injection
and electroporation were used to overexpress wild-type and
several mutant TBC1D1 proteins in mouse tibialis anterior mus-
cles, and glucose transport was measured in vivo.
RESULTS—Expression of the obesity-associated R125W mutant
signiﬁcantly decreased insulin-stimulated glucose transport in
the absence of changes in TBC1D1 PAS phosphorylation. Simul-
taneous expression of an inactive Rab-GTPase (GAP) domain of
TBC1D1 in the R125W mutant reversed this decrease in glucose
transport caused by the R125W mutant. Surprisingly, expression
of TBC1D1 mutated to Ala on four conserved Akt and/or AMP-
activated protein kinase predicted phosphorylation sites (4P)
had no effect on insulin-stimulated glucose transport. In contrast,
expression of the TBC1D1 4P mutant decreased contraction-
stimulated glucose transport, an effect prevented by concomitant
disruption of TBC1D1 Rab-GAP activity. There was no effect of the
R125W mutation on contraction-stimulated glucose transport.
CONCLUSIONS—TBC1D1 regulates both insulin- and contrac-
tion-stimulated glucose transport, and this occurs via distinct
mechanisms. The R125W mutation of TBC1D1 impairs skeletal
muscle glucose transport, which could be a mechanism for the
obesity associated with this mutation. Diabetes 59:1358–1365,
2010
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nsulin and exercise are the most physiologically
relevant stimulators of glucose transport in skeletal
muscle, and in patients with type 2 diabetes, insulin-
but not exercise-stimulated glucose transport can be
severely impaired (1–4). GLUT4 translocation from an
intracellular location to the sarcolemma and transverse
tubules is the major mechanism through which both
insulin and exercise increase glucose transport in muscle
(1,2). Although it is well established that insulin works
through a phosphatidylinositol 3 kinase (PI 3-kinase)–
dependent mechanism and the exercise effect may involve
multiple molecules including the AMP-activated protein
kinase (AMPK) family of protein kinases, an important
goal in this ﬁeld has been to elucidate the mechanisms that
connect the proximal insulin and exercise signals to
GLUT4 translocation. Recent studies have identiﬁed two
molecules, the Akt substrate of 160 kDa (AS160/TBC1D4)
and its paralog, TBC1D1, as potential molecular links
among multiple signaling pathways converging on GLUT4
translocation in skeletal muscle (5–12).
AS160 was ﬁrst shown to modulate GLUT4 trafﬁcking in
insulin-sensitive 3T3-L1 adipocytes (13). A striking struc-
tural feature of AS160 is that the molecule harbors a
Rab-GTPase (GAP) domain and its activity controls Rab-
GTP loading and regulation of Rab function (11). AS160
contains at least six amino acids that can be phosphory-
lated in response to insulin by Akt (14), and these sites can
be detected in aggregate with an antibody directed against
a phospho-Akt substrate motif (PAS). Insulin, exercise, and
the AMPK activator 5-aminoimidazole-4-carboxymide-1--D-
ribofuranoside (AICAR) all cause phosphorylation of
AS160 on PAS sites in skeletal muscle (5,7,10), and there is
good evidence that phosphorylation of these sites inhibits
AS160 activity, leading to trafﬁcking of GLUT4 vesicles to
the cell surface and glucose transport (8,15). However,
ablation of AS160 phosphorylation at PAS sites only
partially inhibits insulin- and contraction-stimulated glu-
cose transport (8,15). Furthermore, a preliminary report
suggests that whole-body knockout of AS160 does not
result in a signiﬁcant increase in glucose transport in
muscle (16). Taken together, these ﬁndings suggest that
there may be one or more additional Rab-GAP proteins
expressed in skeletal muscle that also function to regulate
glucose transport.
TBC1D1 (tre-2/USP6, BUB2, cdc16 domain family mem-
ber 1) is a member of the TBC1 Rab-GAP family of
proteins. TBC1D1 and AS160 are 47% identical overall and
have several comparable structural features. Both proteins
contain two full or partial NH2-terminal phosphotyrosine
binding domains, a splice exon, and a putative calmodulin-
binding domain. The COOH-terminal Rab-GAP domains of
TBC1D1 and AS160 are 79% identical and exhibit similar
Rab speciﬁcities in vitro (6). Both proteins are detected at
a molecular weight of 150–160 kDa upon SDS-PAGE,
and both can be detected using the PAS antibody. Al-
though there are several similarities between TBC1D1 and
AS160, there are also clear differences in tissue distribu-
tion and protein phosphorylation. For example, whereas
AS160 is expressed in multiple tissues at similar levels,
TBC1D1 is several-fold higher in skeletal muscle com-
pared with other tissues (12). Another key difference
between TBC1D1 and AS160 relates to the phosphoryla-
tion status of the proteins. Insulin increases the phosphor-
From the
1Research Division, Joslin Diabetes Center, Boston, Massachusetts;
and the
2Department of Medicine, Brigham and Women’s Hospital and
Harvard Medical School, Boston, Massachusetts.
Corresponding author: Laurie J. Goodyear, laurie.goodyear@joslin.harvard.edu.
Received 26 August 2009 and accepted 2 March 2010. Published ahead of print
at http://diabetes.diabetesjournals.org on 18 March 2010. DOI: 10.2337/
db09-1266.
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
1358 DIABETES, VOL. 59, JUNE 2010 diabetes.diabetesjournals.orgylation of ﬁve of six Akt substrate motifs in AS160,
whereas only one of these insulin-stimulated sites is
conserved in TBC1D1 (6,12,13).
A recent report has shown that a mouse genetic model
resulting in a truncation mutation of TBC1D1 that includes
the Rab-GAP domain of the protein, as well as knockdown
of TBC1D1 in C2C12 muscle cells, lead to increased fatty
acid oxidation (17). Other studies have identiﬁed a genetic
variation in TBC1D1 that confers risk for severe obesity in
Caucasian U.S. and French pedigrees (18,19). This R125W
missense variant occurs in a phosphotyrosine-binding
domain of TBC1D1, but how this mutation leads to meta-
bolic dysfunction and obesity is not known.
Using mass spectrometry, we have identiﬁed novel
phosphorylation sites on TBC1D1 (12), and we and other
laboratories have shown that one or more of these sites
can be regulated by insulin, contraction, and/or AICAR in
skeletal muscle (12,14,20,21). The function of these phos-
phorylation sites is not known. However, given that these
stimuli are potent regulators of glucose transport, that
TBC1D1 is highly expressed in skeletal muscle, and that
R125W mutation of TBC1D1 is associated with obesity, we
hypothesized TBC1D1 regulates glucose transport in skel-
etal muscle. We found distinct mutations of TBC1D1
differentially decrease insulin- and contraction-stimulated
glucose transport in skeletal muscle, and this occurs in a
Rab-GAP domain–dependent manner. Our ﬁndings dem-
onstrate that TBC1D1 functions as a Rab-GAP protein,
regulating both insulin- and contraction-stimulated glu-
cose transport in skeletal muscle.
RESEARCH DESIGN AND METHODS
Animals. Female ICR mice 8–9 weeks old were purchased from Taconic
(Hudson, NY) or Charles River Laboratories (Wilmington, MA). All of the mice
were housed with a 12-h light/12-h dark cycle and fed standard laboratory
chow and water ad libitum. The mice were fasted overnight (9:00 P.M. to 8:00
A.M.) prior to study. Protocols for animal use were reviewed and approved by
the Institutional Animal Care and Use Committee of the Joslin Diabetes
Center and were in accordance with National Institutes of Health guidelines.
Plasmid cDNA constructs. A mouse wild-type TBC1D1 cDNA construct was
generated in our laboratory. Brieﬂy, total RNA was isolated from mouse
tibialis anterior muscle using the RNeasy Fibrous Tissue Mini Kit (74704;
Qiagen). RNA was reverse transcribed to cDNA using the AccuScript High
Fidelity 1st Strand cDNA Synthesis Kit (200820; Stratagene). The long form of
TBC1D1 (AK122445) was ampliﬁed by PCR with the Phusion Hot Start High
Fidelity Polymerase (New England Biolabs) using gene-speciﬁc primers:
forward: 5-ggaaaatagtagcacgttttcctg-3; reverse: 5-ctctgcctctgacttccatct
ctcttg-3. The PCR product was gel puriﬁed with the QIAquick Gel Extraction
Kit (28706; Qiagen) and ligated to the Blunt II Topo cloning vector (K280020;
Invitrogen). The ligation product was transformed into Top10 chemically
competent Escherichia coli (C404003; Invitrogen). Transformants were plated
and screened by selection with kanamycin. Single clones were cultured and
plasmid DNA was extracted with the QIAprep Spin Miniprep Kit (27106;
Qiagen) and sequenced in both the forward and reverse directions (Brigham
and Women’s Sequencing Center, Harvard Medical School). A hemagglutinin
tag was added to the NH2-terminus and XhoI sites to both termini of TBC1D1
by PCR cloning (Phusion) using the following composite primers: forward:
5-tttctcgaggccaccatgtacccgtacgacgtgcccgactacgcg-3; reverse: 5-aaactcgag
ctctgcctctgacttccatctctcttg-3. The PCR product was gel puriﬁed, ligated to the
Blunt II Topo cloning vector, and transformed into Top10 E. coli. True clones
were identiﬁed by plating, kanamycin selection, and sequencing. The hemag-
glutinin-TBC1D1 open reading frame was cut from the Blunt II Topo vector
with XhoI and ligated into the XhoI site of the PCAGGS mammalian expres-
sion vector. True clones were identiﬁed by ampicillin selection of transformed
E. coli (Top10) and sequencing puriﬁed plasmid. This PCAGGS expression
vector drives a target gene under the cytomegalovirus immediate-early
enhancer chicken -actin hybrid (CAG) promoter and has been demonstrated
to have high activity in skeletal muscle (8). Five TBC1D1 mutant constructs
were generated: 1) TBC1D1 mutated to Ala at four phosphorylation motifs
(Ser
231, Thr
499, Thr
590, and Ser
621), rendering these sites incapable of being
phosphorylated (4P); 2) TBC1D1 mutated to Trp at Arg
125 (R125W); 3)
TBC1D1 mutated to Lys at Arg
941 within its Rab-GAP domain to eliminate
TBC1D1 GAP activity (R/K); 4) TBC1D1 double mutant containing both the 4P
and R/K mutations; and 5) TBC1D1 double mutant containing both the R125W
and R/K mutations. TBC1D1 cDNA constructs were sequenced to conﬁrm
accuracy, using the high-throughput DNA sequencing service at Brigham and
Women’s Hospital. Plasmid DNA was ampliﬁed in E. coli Top10 cells
(Invitrogen), extracted using an endotoxin-free Plasmid Mega Kit (Qiagen),
and suspended in saline at 4 g/l. TBC1D1 plasmids (100 g) were injected
into mouse tibialis anterior muscles using our protocol (22), modiﬁed to that
originally described by Aihara and Miyazaki (23), and mice were studied 7
days later.
Contraction, glucose, and insulin treatment in the study of PAS
phosphorylation. Mice were anesthetized with intraperitoneal administra-
tion of pentobarbital sodium (90 mg/kg of body wt). Peroneal nerves from
both legs were surgically exposed for electrode placement. One leg was left
unstimulated (basal/sham control) and the other leg was subjected to electri-
cal stimulation using a Grass S88 pulse generator for 15 min of contractions
(train rate 1/s; train duration 500 ms; pulse rate 100 Hz; duration 0.1 ms at 2–7
V), as we have previously described (5). To study insulin-activated PAS
signaling, we injected mice with either a bolus of glucose that resulted in a
physiological increase in plasma insulin concentrations (8) or an insulin bolus.
For the glucose treatment, mice were anesthetized and administered a 20%
glucose bolus (1.0 g of glucose/kg of body wt). For the insulin treatment, mice
were anesthetized and injected with insulin (10 mU/g). Immediately after
contraction, 15 min after glucose administration, or 6 min after insulin
stimulation, tibialis anterior muscles were dissected and frozen in liquid
nitrogen.
Protein extraction, immunoprecipitation, and immunoblotting. Frozen
muscle tissue was homogenized with a Polytron (Brinkman Instruments) in
lysis buffer, as described previously (12). Homogenates were centrifuged at
14,000g for 10 min and supernatants were collected. Protein concentrations
were determined by the Bradford assay. In some experiments, lysates were
subjected to immunoprecipitation to remove AS160 before separation by
SDS-PAGE. AS160 was immunoprecipitated with a Rabbit polyclonal antibody
(07–741; Millipore, Billerica, MA). Bead-antibody-protein complexes were
washed 1 with lysis buffer, 2 with lysis buffer  500 mmol/l NaCl, and 1
with lysis buffer. Pellets were aspirated and spotted with 5–10 lo f1g/l
BSA before elution. Proteins were eluted from protein G beads by adding
Laemmli buffer and heated for 5 min at 95°C. For immunoblotting, lysates (50
g protein) were separated by SDS-PAGE for Western blot analysis. Antibody-
bound proteins were visualized, using enhanced chemiluminescence (Amer-
sham Biosciences). The protein bands were scanned by ImageScanner
(Amersham Biosciences) and quantitated by densitometry (Fluorchem 2.0;
Alpha Innotech, San Leandro, CA).
Antibodies. Protein expression was assessed with antibodies to AS160
(07–741; Millipore), GLUT4 and GLUT1 (AB1346 and CBL242, respectively;
Chemicon International), AMPK 2 (07–363; Upstate Biotechnology, Inc.), and
Akt1/2, hexokinase II, and anti–-tubulin (SC1619, SC6521, and SC5286,
respectively; Santa Cruz Biotechnology). Serum-puriﬁed anti-TBC1D1 anti-
body was generated by Cell Signaling Technology by immunizing rabbits (12).
Phosphorylation-speciﬁc antibodies included Akt Thr
308 (9275), Akt Ser
473
(4058), AMPK Thr
172 (2535), and PAS (9611) from Cell Signaling Technology.
Horseradish peroxidase–conjugated anti-rabbit, anti-mouse, and anti-goat
antibodies (Amersham Biosciences) were used to bind and detect all primary
antibodies.
In vivo skeletal muscle and glucose transport. Glucose transport was
measured, as we previously described (5). Brieﬂy, mice were fasted overnight
and anesthetized with intraperitoneal administration of pentobarbital sodium
(90 mg/kg of body wt). To examine contraction-stimulated glucose transport,
muscle was contracted, as described above. To study insulin-stimulated
glucose transport, mice were administered a saline or 20% glucose bolus (1.0
g of glucose/kg of body wt), along with [
3H]-2-deoxyglucose through the
retro-orbital sinus. Our previous studies have shown that this dosage stimu-
lates a physiologic insulin response (75 U/ml) without inducing signiﬁcant
hypoglycemia (8). Baseline blood samples were collected from the tail vein
prior to retro-orbital injection. The blood samples were collected from the tail
vein at 5, 10, 15, 25, 35, and 45 min after injection to determine blood glucose
and [
3H]-2-deoxyglucose–speciﬁc activity. Subsequently, the animals were
killed, and tibialis anterior muscles were removed and frozen in liquid
nitrogen. Muscles were subsequently lysed and glucose transport ([
3H]-2-
deoxyglucose-P) was determined via a precipitation protocol adapted from
Ferre ´ et al. (24).
Statistical analysis. Data are expressed as the means  SE. Means were
compared by one-way or two-way ANOVA. When ANOVA revealed signiﬁcant
differences, Tukey post hoc test for multiple comparisons was performed. P
values less than 0.05 were considered statistically signiﬁcant.
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Overexpression of TBC1D1 in mouse tibialis anterior
muscle. To study TBC1D1 function in skeletal muscle, in
vivo injection and electroporation were used to transfect
mouse tibialis anterior muscles with recombinant wild-
type TBC1D1 and ﬁve TBC1D1 mutants. The TBC1D1
mutants were 1) TBC1D1 mutated to Trp at Arg
125
(R125W); 2) TBC1D1 mutated to Ala at four phosphoryla-
tion motifs (Ser
231, Thr
499, Thr
590, and Ser
621); 3) TBC1D1
mutated to Lys at Arg
941 within its Rab-GAP domain (R/K);
4) TBC1D1 double mutant containing both the R125W and
R/K mutations; and 5) TBC1D1 double mutant containing
both the 4P and R/K mutations. We selected the 4P mutant
sites because these sites are highly conserved and are
predicted to be phosphorylated by AMPK and/or Akt (i.e.,
Ser
231 and Thr
499 by AMPK, Thr
590 by Akt, and Ser
621 by
both AMPK and Akt) (12). In vivo DNA injection and
electroporation resulted in an approximate sevenfold in-
crease in expression of TBC1D1 in mouse tibialis anterior
muscle compared with endogenous TBC1D1 (Fig. 1). The
magnitude of overexpression was comparable across all
constructs, as each TBC1D1 variant was subcloned into
the same pCAGGS vehicle.
TBC1D1 PAS phosphorylation. We ﬁrst determined the
effects of overexpressing wild-type and mutant TBC1D1
proteins on the phosphorylation state of TBC1D1, using
the PAS antibody. Because the PAS antibody detects both
AS160 and TBC1D1, AS160 was depleted from lysates by
immunoprecipitation. After immunoprecipitation, AS160 was
not detected in the muscle lysates and there was no effect of
the AS160 immunoprecipitation on the TBC1D1 protein, as
detected by immunoblotting (supplementary Fig. 1, available
in an online appendix at http://diabetes.diabetesjournals.org/
content/early/2010/03/10/db09-1266/suppl/DC1). The AS160-
depleted lysates were used to study TBC1D1 PAS signaling.
As expected, basal phosphorylation was signiﬁcantly in-
creased in muscles overexpressing wild-type, R/K, R125W,
and R125W/RK TBC1D1 mutants compared with empty
vector controls (Fig. 2A and B). Glucose injection resulting
in physiological insulin concentrations (Fig. 2A), contrac-
tion (Fig. 2B), and maximal insulin (supplementary Fig.
2A) stimulated endogenous TBC1D1 PAS phosphorylation
by 1.5- to 2-fold. PAS phosphorylation in response to the
three stimuli was greater in muscles overexpressing wild-
type, R/K, R125W, and R125W/RK TBC1D1 (Fig. 2A and B;
supplementary Fig. 2A). PAS phosphorylation in the 4P
and 4P/RK TBC1D1-expressing muscle was not increased
in the basal state compared with empty vector controls.
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FIG. 1. TBC1D1 expression was signiﬁcantly increased in mouse
tibialis anterior muscles in response to in vivo cDNA injection and
electroporation. Empty pCAGGS vector (EV) and TBC1D1 cDNA con-
structs (wild-type [WT] and 4P, R125W, R/K, 4P/RK, and R125W/RK
mutants) were injected into the tibialis anterior muscles of anesthe-
tized mice, followed by in vivo electroporation. The animals were
allowed to recover, and protein expression was assessed 1 week after
injection. Muscle proteins were separated by SDS-PAGE and immuno-
blotted with an anti-TBC1D1 antibody. The data are expressed as the
means  SE; n  8–12/group. #P < 0.05 (vs. empty vector controls).
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FIG. 2. Phosphorylation of TBC1D1 in transfected muscles. To determine whether expression of TBC1D1 altered TBC1D1 PAS phosphorylation,
EV and TBC1D1 cDNA constructs were injected into tibialis anterior muscles followed by in vivo electroporation, and mice were studied 1 week
later. A: Mice were anesthetized and injected intravenously with saline () or glucose (; 1.0 g of glucose/kg of body wt), and tibialis anterior
muscles were obtained 15 min later. B: Mice were anesthetized, one leg was sham treated () and the other leg was contracted in situ () for
15 min, and tibialis anterior muscles were dissected. Muscle lysates were immunoprecipitated to deplete AS160 and supernatants were separated
by SDS-PAGE and immunoblotted with an anti-PAS antibody. White bars represent basal treatment, and black bars represent glucose/insulin (A)
or contraction (B) treatment groups. Data are means  SE, n  8. *P < 0.05 (vs. basal); #P < 0.05 (vs. empty vector for respective treatment).
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signiﬁcantly increase PAS phosphorylation in the 4P over-
expressing muscles (Fig. 2A and B; supplementary Fig.
2A). These data demonstrate that the recombinant
TBC1D1 is functionally modiﬁed in vivo, and that the
integrity of the TBC1D1 point mutations (4P and 4P/RK)
was preserved after gene expression. The R125W and R/K
mutations did not interfere with the ability of insulin and
contraction to increase PAS phosphorylation in the skele-
tal muscle.
TBC1D1 regulates insulin-stimulated glucose trans-
port. Although there is minimal expression of TBC1D1 in
adipocytes (12,16), a previous study has shown that over-
expression of wild-type TBC1D1 dramatically reduces
insulin-stimulated GLUT4 translocation in 3T3L1 adipo-
cytes (6). In contrast to these ﬁndings, we found that
overexpression of wild-type TBC1D1 did not decrease
basal or submaximal insulin-stimulated glucose transport
in skeletal muscle (Fig. 3A).
Insulin and contraction increase TBC1D1 and AS160
phosphorylation as detected in aggregate by the PAS
antibody (5,12), and abolishing AS160 PAS phosphoryla-
tion impairs insulin- and contraction-induced glucose
transport (8). Because of the structural similarity of
TBC1D1 to AS160, we hypothesized that TBC1D1 phos-
phorylation sites detected by the PAS antibody would also
be important for glucose transport. To address this ques-
tion, we overexpressed the TBC1D1 4P construct that
results in the loss of insulin- and contraction-stimulated
PAS phosphorylation (Fig. 2) and measured basal and
submaximal insulin-stimulated glucose transport in vivo.
Surprisingly, expression of the TBC1D1 4P mutant did not
alter insulin-stimulated glucose transport (Fig. 3A).
Genetic linkage analyses have shown a TBC1D1 R125W
missense variant is linked to severe obesity in humans
(18,19). Because skeletal muscle is the tissue with the
highest level of expression of TBC1D1, we tested the
hypothesis that the R125W mutation would alter glucose
transport in this tissue. We found that overexpression of
the TBC1D1 R125W mutant in skeletal muscle signiﬁcantly
impaired insulin-stimulated glucose transport (Fig. 3A). To
explore whether disruption of the Rab-GAP domain re-
verses the decrease in glucose transport associated with
the R125W mutation, we expressed TBC1D1 containing
both the R125W and Rab-GAP mutations in the muscles.
Figure 3B shows that glucose/insulin-stimulated glucose
transport was normalized when the TBC1D1 R125W mu-
tant was coexpressed with the mutated Rab-GAP domain.
Interestingly, expression of TBC1D1 with a disrupted
Rab-GAP domain (R/K) signiﬁcantly increased basal glu-
cose transport without altering insulin-stimulated glucose
transport (Fig. 3B).
TBC1D1 regulates contraction-stimulated glucose
transport. We examined whether TBC1D1 regulates con-
traction-stimulated glucose transport. The contraction
protocol used was maximal, and therefore the increase in
glucose transport with contraction was greater than with
glucose-induced physiological insulin (Figs. 3 and 4).
Similar to the effects of insulin, expression of wild-type
TBC1D1 did not alter contraction-stimulated glucose
transport (Fig. 4A). However, in contrast to what was
observed with glucose/insulin, muscles overexpressing the
TBC1D1 4P mutant exhibited a signiﬁcant decrease in
contraction-stimulated glucose transport (Fig. 4A). Fur-
thermore, although the expression of the TBC1D1 R125W
mutation decreased insulin-induced glucose transport,
it did not alter contraction-induced glucose transport
(Fig. 4A).
TBC1D1 devoid of Rab-GAP activity signiﬁcantly in-
creased contraction-stimulated glucose transport by 60%
(Fig. 4B). In addition, disruption of the Rab-GAP domain
of TBC1D1 resulted in reversal of the decrease in contrac-
tion-stimulated glucose transport that occurred with ex-
pression of the 4P mutant (Fig. 4B). These results suggest
that TBC1D1 plays an important role in contraction-
stimulated glucose transport.
For the contraction experiments, all treatment groups
had a higher basal rate of glucose transport compared with
the basal glucose transport in the insulin experiment. This
is likely the result of contraction of one leg altering
glucose transport of the control sedentary leg due to
changes in blood ﬂow or concentration of blood hor-
mones. Therefore, the higher basal rates of glucose trans-
port in the contraction experiments may mask the more
prominent effects of the Rab-GAP (R/K) mutant that are
observed with the insulin experiments.
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FIG. 3. Overexpression of TBC1D1 altered insulin-stimulated glucose transport in mouse skeletal muscles. To determine whether expression of
wild-type TBC1D1 and TBC1D1 mutants altered insulin-stimulated glucose transport, EV or TBC1D1 cDNA constructs were injected into tibialis
anterior muscles followed by in vivo electroporation. One week later, mice were anesthetized and administered a saline or 20% glucose bolus (1.0
g of glucose/kg of body wt) through the retro-orbital sinus to stimulate a physiologic insulin response. Insulin-stimulated glucose transport was
measured in tibialis anterior muscles using [
3H]2-deoxyglucose. A: The effects of expressing the 4P and R125W mutants. B: The effects of the
Rab-GAP (R/K) mutants. White bars represent the basal treatment, and black bars represent the glucose/insulin treatment group. Data are
means  SE, n  8–16 mice/group. *P < 0.05 (vs. basal); #P < 0.05 (vs. empty vector for respective treatment).
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ing proteins and glucose transport. Akt plays a key role
in mediating insulin-stimulated glucose transport, whereas
the signaling mechanisms regulating contraction-induced
glucose transport likely involve AMPK and AMPK-related
kinases. To determine whether overexpression of the
TBC1D1 constructs alter insulin- and contraction-stimu-
lated Akt and AMPK signaling, Akt-Thr
308, Akt-Ser
473, and
AMPK Thr
172 phosphorylation were measured in muscles
expressing the TBC1D1 constructs. Insulin-stimulated
(supplementary Fig. 2B and C) or glucose-stimulated (sup-
plementary Fig. 3) Akt Thr
308 and Akt Ser
473 phosphory-
lation were not altered in muscles expressing wild-type
and mutant TBC1D1. In addition, contraction-induced
AMPK Thr
172 phosphorylation (supplementary Fig. 4A)
and Akt Thr
308 and Akt Ser
473 phosphorylation (supple-
mentary Fig. 4B and C) were also normal in the muscles.
These results indicate that TBC1D1 mutations alter glu-
cose transport without interfering with Akt and AMPK
signaling.
AS160 mutated at four PAS phosphorylation sites signif-
icantly decreases insulin- and contraction-stimulated glu-
cose transport in skeletal muscle (8). Therefore, we
determined whether overexpression of wild-type or mu-
tant TBC1D1 would alter AS160 protein expression and/or
insulin- and contraction-stimulated AS160 PAS phosphor-
ylation. AS160 was immunoprecipitated from tibialis ante-
rior muscle lysates expressing wild-type and mutant
TBC1D1 and immunoblotted with the PAS antibody. Stim-
ulation of AS160 phosphorylation by insulin (supplemen-
tary Fig. 5A) and contraction (supplementary Fig. 5B) was
not affected by overexpression of wild-type or mutant
TBC1D1. Overexpression of TBC1D1 had no effect on
AS160 protein expression (supplementary Fig. 6). These
results suggest that TBC1D1 alters glucose transport with-
out altering AS160 PAS phosphorylation.
GLUT proteins and glycolytic enzymes can be critical
regulators of glucose metabolism in skeletal muscle.
Therefore, we determined whether TBC1D1 overexpres-
sion alters the protein expression of GLUT1, GLUT4, or
hexokinase II in the transfected muscles. As shown in
supplementary Fig. 6, there was no difference in expres-
sion among muscles injected with empty vector or any of
the TBC1D1 constructs. Therefore, TBC1D1 overexpres-
sion does not alter expression of these key regulatory
proteins of glucose metabolism in skeletal muscle.
DISCUSSION
Under normal physiological conditions, skeletal muscle
glucose transport is the rate-limiting step in glucose utili-
zation, and impairment in insulin-stimulated glucose trans-
port in this tissue is a major factor in the development of
type 2 diabetes. Despite the importance of skeletal muscle
in metabolic health, the intracellular signaling mecha-
nisms regulating glucose transport in this tissue are not
completely understood. TBC1D1 is a Rab-GAP protein and
a paralog of AS160, the latter protein having recently been
recognized as a critical regulator of glucose transport in
both adipocytes and skeletal muscle (8,13,15,25). Although
TBC1D1 is known to have the highest levels of expression
in skeletal muscle and is phosphorylated in response to
multiple factors that stimulate glucose transport in skele-
tal muscle (12), whether TBC1D1 functions in the regula-
tion of glucose transport in adult skeletal muscle was not
clear. A recent study using a mouse model with a TBC1D1
truncation mutation (SJL) showed that depletion of
TBC1D1 in skeletal muscle increased fatty acid oxidation
but decreased glucose utilization (17). Because muscle
from the SJL mouse has decreased GLUT4 expression, it is
not known whether alterations in TBC1D1 function con-
tributed to the inhibition of glucose uptake observed in the
extensor digitorum longus muscle (17). In the current
study, there was no change in GLUT4 expression, and
therefore, TBC1D1 was established as a regulator of both
insulin- and contraction-stimulated glucose transport in
skeletal muscle.
Numerous phosphorylation sites have been identiﬁed on
TBC1D1 (6,12,22), but the potential role of these sites in
the regulation of glucose transport in skeletal muscle is
not known. To determine whether TBC1D1 phosphoryla-
tion regulates glucose transport, we mutated Ser
231,
Thr
499, Thr
590, and Ser
621 to Ala to inhibit their phosphor-
ylation (4P). We chose these sites because they 1) are
highly conserved phosphorylation sites on TBC1D1; 2) are
not subject to splice variation; and 3) represent predicted
G
l
u
c
o
s
e
 
T
r
a
n
s
p
o
r
t
(
n
g
 
g
l
u
c
o
s
e
/
m
g
 
t
i
s
s
u
e
/
4
5
 
m
i
n
)
0
500
1000
1500
2000
4P R125W
*
* *
*
#
A
G
l
u
c
o
s
e
 
T
r
a
n
s
p
o
r
t
(
n
g
 
g
l
u
c
o
s
e
/
m
g
 
t
i
s
s
u
e
/
4
5
 
m
i
n
)
0
500
1000
1500
2000
2500
3000
EV EV WT 4P/RK 4P R/K
*
# #
*
* *
#
B
FIG. 4. Overexpression of TBC1D1 altered contraction-stimulated glucose transport in mouse skeletal muscles. To determine whether expression
of wild-type TBC1D1 and TBC1D1 mutants altered contraction-stimulated glucose transport, EV or TBC1D1 cDNA constructs were injected into
tibialis anterior muscles followed by in vivo electroporation. One week later, mice were anesthetized and contraction was performed by
stimulation of the peroneal nerve. One leg was sham treated but unstimulated, and the other leg was contracted for 15 min. Contraction-
stimulated glucose transport was measured in tibialis anterior muscles using [
3H]2-deoxyglucose. A: The effects of expressing the 4P and R125W
mutants. B: The effects of the Rab-GAP (R/K) mutants. White bars represent the basal treatment, and black bars represent the contraction
treatment group. Data are means  SE, n  8–16 mice/group. *P < 0.05 (vs. basal); #P < 0.05 (vs. empty vector for respective treatment).
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sites, Thr
590, a predicted Akt motif, is phosphorylated in
response to insulin, and corresponds to Thr
649 in AS160
(12). TBC1D1 Ser
621 is a partial match for both the Akt and
AMPK recognition motifs (12). Given the importance of
the Akt sites on AS160 in the regulation of glucose
transport (8,13), we were surprised to ﬁnd that expression
of this TBC1D1 4P mutant had no effect on insulin-
stimulated glucose transport. Thus, our ﬁndings suggest
that either TBC1D1 phosphorylation is not required for
insulin-stimulated glucose transport due to the existence
of another Rab-GAP protein or there are other Akt sites on
TBC1D1 that are critical to mediate insulin-induced glu-
cose transport. In contrast, expression of the TBC1D1 4P
mutant signiﬁcantly decreased contraction-stimulated glu-
cose transport and this decrease was completely reversed
by concomitant disruption of TBC1D1 Rab-GAP activity. It
is possible that Ser
231 and/or Thr
499 mediate this inhibition
because these sites are predicted to be phosphorylated by
AMPK, and muscle contraction is a potent stimulus for
AMPK activation. Taken together, our data suggest that
phosphorylation of the putative AMPK sites Ser
231 and/or
Thr
499, but not Thr
590 and Ser
621, may be critical in
regulating TBC1D1 Rab-GAP activity and glucose trans-
port. These ﬁndings also raise the possibility that TBC1D1
phosphorylation on Ser
231 and/or Thr
499 function predom-
inantly in the regulation of contraction effects on glucose
transport, whereas the phosphorylation of AS160 may be
key in regulating insulin-stimulated glucose transport.
A TBC1D1 R125W missense variant causes familial
obesity predisposition in humans (18,19); however, the
mechanism by which this mutation leads to obesity is not
known. Our ﬁnding that expression of the R125W mutation
in skeletal muscle impairs insulin-stimulated glucose
transport and our previous work showing that TBC1D1 is
abundant only in skeletal muscle (12) suggest that meta-
bolic dysfunction in skeletal muscle caused by alterations
in TBC1D1 function could be a primary phenotypic mani-
festation of the TBC1D1 R125W missense variant. Impair-
ment of glucose transport in muscle could lead to
increased fat accumulation in adipose tissue, and subse-
quent obesity. Although the precise molecular mechanism
by which the R125W mutation in TBC1D1 impairs insulin-
stimulated glucose transport is not known, it is interesting
to note that this mutation does not result in defects in
upstream insulin signaling, as Akt phosphorylation was
normal.
In contrast to insulin, expression of the TBC1D1 R125W
mutant had no effect on contraction-stimulated glucose
transport in mouse skeletal muscle, and this difference
may provide important clues as to the mechanism by
which the R125W mutation causes defects in glucose
transport. This difference in R125 function for insulin- and
contraction-stimulated glucose transport is likely due to
distinct proximal signals for insulin and contraction. Insu-
lin-stimulated glucose transport involves insulin binding to
its receptor and subsequent activation of insulin receptor
substrate, PI 3-kinase, and Akt (26,27). In contrast, con-
traction-stimulated glucose transport cannot be inhibited
by the PI 3-kinase inhibitor wortmannin, and although the
exact mechanism is still not fully understood, it may be
mediated through AMPK or other AMPK-related kinases
(1,28,29). Therefore, insulin and contraction may phos-
phorylate TBC1D1 on distinct sites, which may lead to
different effects on its Rab-GAP activity or result in differ-
ent afﬁnities of TBC1D1 for other proteins. The R125 site is
located in a tyrosine-binding domain in TBC1D1. Given
that this domain mediates binding of AS160 with other
proteins (25,30–32), the R125W mutation may alter the
afﬁnity of TBC1D1 for proteins involved in insulin but not
contraction signaling, resulting in impaired insulin-stimu-
lated glucose transport. The mechanism by which the
R125W mutation impairs glucose transport will be an
important topic for future investigation. Our ﬁnding that
the impairment of insulin-stimulated glucose transport
could be reversed by simultaneous disruption of Rab-GAP
activity in TBC1D1 suggests a possible therapeutic ap-
proach to treat patients with this condition in the future.
Our results show that overexpression of wild-type
TBC1D1 had no effect on both insulin- and contraction-
stimulated glucose transport, in contrast to previous stud-
ies using adipocytes (6,16). The discrepancy is likely
because there are very different expression levels of
endogenous TBC1D1 in skeletal muscle and adipocytes.
We ﬁnd little to no expression of TBC1D1 in adipose tissue
(12), and it has been reported that adipocytes have 20
times more AS160 compared with TBC1D1 (16). Thus,
overexpression of a large amount of TBC1D1 in adipocytes
may interfere with AS160 phosphorylation, suppressing
GLUT4 translocation, resulting in inhibition of glucose
transport. If TBC1D1 functions as a brake to restrain
GLUT4 translocation and adipocytes lack this protein,
overexpressing this foreign protein may overwhelm the
system, preventing GLUT4 translocation. In contrast, in
mouse skeletal muscle, expression of endogenous
TBC1D1 is so abundant that it is sufﬁcient to inhibit
GLUT4 translocation. Therefore, overexpression of wild-
type TBC1D1 in skeletal muscle did not inhibit glucose
transport as it did in adipocytes. In addition, in 3T3-L1
adipocytes, mutation of R125W had no further effect on
insulin-stimulated glucose transport compared with wild-
type TBC1D1 (33). It is likely that in adipocytes, overex-
pression of wild-type TBC1D1 inhibits glucose transport
enough to mask the effect of the R125W mutation on
glucose transport. Indeed, in our studies in skeletal mus-
cle, expressing the TBC1D1 R125W mutant signiﬁcantly
decreased insulin-stimulated glucose transport, under con-
ditions where there was no effect of wild-type TBC1D1.
Thus, the studies using adipocytes should be interpreted
with caution and not extrapolated to skeletal muscle
because TBC1D1 is minimally expressed in adipocytes and
because the TBC1D1 splice variant expressed in the
adipocyte study is not the variant expressed in skeletal
muscle (6).
The current work suggests that in addition to AS160,
TBC1D1 functions as a Rab-GAP protein regulating glu-
cose transport in mouse skeletal muscle. In comparing
TBC1D1 with AS160, mutation of four Akt phosphoryla-
tion sites on AS160 inhibited both insulin- and contraction-
stimulated glucose transport, and both of these effects
were reversed by disruption of the Rab-GAP domain (8). In
contrast, in the current study, mutations of four phosphor-
ylation sites on TBC1D1, which consisted of both pre-
dicted Akt and AMPK sites, impaired only contraction-
stimulated glucose transport. One explanation for this
ﬁnding is that TBC1D1 phosphorylation may not mediate
insulin-stimulated glucose transport in mouse skeletal
muscle. The second possibility is that the mutation of the
two putative Akt sites (Thr
590 and Ser
621) is insufﬁcient to
inhibit Rab-GAP activity of this protein, and that there
must be one or more additional putative Akt sites in
TBC1D1 that also regulate its Rab-GAP activity after
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to investigate the regulation and function of additional
phosphorylation sites on TBC1D1. In addition, because
different muscles have different relative levels of expres-
sion of AS160 and TBC1D1, these two Rab-GAP domains
may contribute differently in terms of glucose transport in
various muscle types.
In summary, we used in vivo gene injection and electro-
poration to overexpress wild-type and mutant TBC1D1 in
mouse tibialis anterior muscles and evaluated the effect of
TBC1D1 on glucose transport. Our studies show that the
R125W mutation in TBC1D1 impairs insulin-stimulated
glucose transport and has no effect on contraction-stimu-
lated glucose transport, which may be a major mechanism
for the obesity associated with this mutation. In contrast,
mutation of four conserved phosphorylation sites compro-
mised only contraction-stimulated glucose transport. Fur-
thermore, we ﬁnd that the Rab-GAP domain of TBC1D1 is
critical in the regulation of glucose transport in muscle.
TBC1D1 mediates stimuli-speciﬁc upstream signals, lead-
ing to regulation of glucose transport. Taken together with
the reported role of this protein in fatty acid metabolism,
TBC1D1 is a central regulator of metabolic function in
skeletal muscle.
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